Table 2. Mutation status of BRAF, NRAS and KRAS genes in 19 sequentially analyzed patients.

Sample name	Disease stage	BRAF status	KRAS status	NRAS status
MM-004	MM onset	wild type	G12S, 9.18%	wild type
	MM relapse	wild type	wild type	wild type
MM-146	MM onset	wild type	G12V, 24.58%	Q61H, 6.11%
	MM relapse	wild type	wild type	Q61H, 40.78%
MM-151	MM onset	wild type	G13D, 9.35%; Q61H, 35.29%	wild type
	MM relapse	wild type	Q61H, 42.79%	wild type
MM-200	MM onset	wild type	Q61H, 23.74%	wild type
	MM relapse	wild type	Q61H, 28.49%; Q61L, 5.07%	wild type
MM-239	MM onset	wild type	wild type	wild type
	MM relapse	wild type	wild type	wild type
MM-263	MM onset	wild type	wild type	wild type
	MM relapse	wild type	wild type	wild type
MM-271	MM onset	wild type	wild type	wild type
	MM relapse	wild type	wild type	wild type
MM-280	MM onset	wild type	Q22K, 50%	wild type
	MM relapse	wild type	Q22K, 31.41%	wild type
MM-282	MM onset	wild type	wild type	wild type
	MM relapse	wild type	wild type	wild type
MM-286	MM onset	wild type	wild type	wild type
	MM relapse	wild type	wild type	wild type
MM-327	MM onset	wild type	Q61H, 37.34%	Q61K, 4.28%
	MM relapse	wild type	Q61H, 38.15%	wild type
MM-334	MM onset	wild type	wild type	G12D, 96.49%
	MM relapse	wild type	wild type	G12D, 92.94%
MM-340	MM onset	wild type	wild type	wild type
	MM relapse	wild type	G12A, 4.23%; G12R, 10.05%	wild type
MM-429	MM onset	wild type	G12D, 21.47%	wild type
	MM relapse	wild type	wild type	Q61R, 46%; E62Kfs*6, 4.09%
MM-295	MM onset	D594N, 50%	wild type	G12D, 8.89%
	MM leukemic transformation	D594N, 51.88%	wild type	G12D, 100%
MM-281	MM onset	wild type	wild type	wild type
	MM leukemic transformation	wild type	wild type	wild type
PCL-026	pPCL onset	D594N, 43.05%; E586K, 42.15%	wild type	wild type
	pPCL relapse	D594N, 40%; E586K, 42.8%	wild type	wild type
PCL-038	pPCL onset	wild type	G12R, 42.42%	wild type
	pPCL relapse	wild type	G12R, 43.17%	wild type
MM-442	MM leukemic transformation	wild type	Q61H, 45.93%	wild type
	sPCL relapse	wild type	Q61H, 52.75%	wild type